COVID-19 Early Treatment Options
Micky Turner made this Official Information request to Ministry of Health
The request was successful.
From: Micky Turner
Dear Ministry of Health,
Can you please advise if you are offering people with Covid-19 any of the following:
Fluvoxamine 89%
Budesonide 81%
Vitamin D 81%
Vitamin A 79%
Quercetin 79%
Melatonin 78%
Zinc 74%
Povidone-Iodine 71%
Sotrovimab 67%
Ivermectin 67%
Vitamin C 43%
Aspirin 21%
I have included their early treatment efficacy % beside each one. This information can be found at c19early.com
These vitamins and OTC meds should be given in a pack to every one with Covid 19 and their close contacts:
Vitamin D 81%
Vitamin A 79%
Quercetin 79%
Melatonin 78%
Zinc 74%
Povidone-Iodine 71%
Vitamin C 43%
Aspirin 21%
The Ministry of Health should also have enough Budesonide and inhalers for 100,000 people.
- Micky Turner
From: OIA Requests
Kia ora,
Thank you for your Official Information Act (the Act) request. This is
an automatic reply to let you know we received it.
Due to the COVID-19 global pandemic response, the Ministry is experiencing
significantly higher volumes of queries and requests for information. We
will endeavour to acknowledge your request as soon as possible. Further
information about COVID-19 can be found on our
website: [1]https://www.health.govt.nz/our-work/dise...
In accordance with the Act, we'll let you know our decision within no more
than 20 working days. If you'd like to calculate the timeframe, you can
use the Ombudsman's online calculator
here: [2]http://www.ombudsman.parliament.nz/
If you have any questions while we're processing your request, please let
us know via [3][email address]
Ngā mihi
OIA Services Team
[4]Ministry of Health information releases
[5]Unite against COVID-19
****************************************************************************
Statement of confidentiality: This e-mail message and any accompanying
attachments may contain information that is IN-CONFIDENCE and subject to
legal privilege.
If you are not the intended recipient, do not read, use, disseminate,
distribute or copy this message or attachments.
If you have received this message in error, please notify the sender
immediately and delete this message.
****************************************************************************
--------------------------------------------------------------------------
This e-mail message has been scanned for Viruses and Content and cleared
by the Ministry of Health's Content and Virus Filtering Gateway
--------------------------------------------------------------------------
References
Visible links
1. https://www.health.govt.nz/our-work/dise...
2. http://scanmail.trustwave.com/?c=15517&a...
3. mailto:[email address]
4. https://www.health.govt.nz/about-ministr...
5. https://covid19.govt.nz/
hide quoted sections
From: OIA Requests
Kia ora Micky,
Thank you for your request for official information. The Ministry's
reference number for your request is: H202116568.
As required under the Official Information Act 1982, the Ministry will
endeavour to respond to your request no later than 20 working days after
the day your request was received. If you'd like to calculate the
timeframe, you can use the Ombudsman's online calculator
here: [1]http://www.ombudsman.parliament.nz/
Due to the COVID-19 global pandemic response, the Ministry is experiencing
significantly higher volumes of queries and requests for information. If
we are unable to respond to your request within this time frame, we will
notify you of an extension of that time frame.
If you have any queries related to this request, please do not hesitate to
get in touch.
Ngā mihi
OIA Services
Government Services
Office of the Director-General
Ministry of Health
E: [2][email address]
-----Original Message-----
From: Micky Turner <[FOI #17557 email]>
Sent: Saturday, 13 November 2021 6:53 pm
To: OIA Requests <[email address]>
Subject: Official Information request - COVID-19 Early Treatment Options
Dear Ministry of Health,
Can you please advise if you are offering people with Covid-19 any of the
following:
Fluvoxamine 89%
Budesonide 81%
Vitamin D 81%
Vitamin A 79%
Quercetin 79%
Melatonin 78%
Zinc 74%
Povidone-Iodine 71%
Sotrovimab 67%
Ivermectin 67%
Vitamin C 43%
Aspirin 21%
I have included their early treatment efficacy % beside each one. This
information can be found at
[3]http://scanmail.trustwave.com/?c=15517&a...
These vitamins and OTC meds should be given in a pack to every one with
Covid 19 and their close contacts:
Vitamin D 81%
Vitamin A 79%
Quercetin 79%
Melatonin 78%
Zinc 74%
Povidone-Iodine 71%
Vitamin C 43%
Aspirin 21%
The Ministry of Health should also have enough Budesonide and inhalers for
100,000 people.
- Micky Turner
-------------------------------------------------------------------
This is an Official Information request made via the FYI website.
Please use this email address for all replies to this request:
[4][FOI #17557 email]
Is [5][Ministry of Health request email] the wrong address for Official Information
requests to Ministry of Health? If so, please contact us using this form:
[6]https://scanmail.trustwave.com/?c=15517&...
Disclaimer: This message and any reply that you make will be published on
the internet. Our privacy and copyright policies:
[7]https://scanmail.trustwave.com/?c=15517&...
If you find this service useful as an Official Information officer, please
ask your web manager to link to us from your organisation's OIA or LGOIMA
page.
-------------------------------------------------------------------
****************************************************************************
Statement of confidentiality: This e-mail message and any accompanying
attachments may contain information that is IN-CONFIDENCE and subject to
legal privilege.
If you are not the intended recipient, do not read, use, disseminate,
distribute or copy this message or attachments.
If you have received this message in error, please notify the sender
immediately and delete this message.
****************************************************************************
--------------------------------------------------------------------------
This e-mail message has been scanned for Viruses and Content and cleared
by the Ministry of Health's Content and Virus Filtering Gateway
--------------------------------------------------------------------------
References
Visible links
1. http://www.ombudsman.parliament.nz/
2. mailto:[email address]
3. http://scanmail.trustwave.com/?c=15517&a...
4. mailto:[FOI #17557 email]
5. mailto:[Ministry of Health request email]
6. https://scanmail.trustwave.com/?c=15517&...
7. https://scanmail.trustwave.com/?c=15517&...
hide quoted sections
From: OIA Requests
Tçnâ koe Micky
Thank you for your request under the Official Information Act 1982 (the
Act) to the Ministry of Health (the Ministry) on 13 November 2021 for:
“Can you please advise if you are offering people with Covid-19 any of the
following:
Fluvoxamine 89%
Budesonide 81%
Vitamin D 81%
Vitamin A 79%
Quercetin 79%
Melatonin 78%
Zinc 74%
Povidone-Iodine 71%
Sotrovimab 67%
Ivermectin 67%
Vitamin C 43%
Aspirin 21%
I have included their early treatment efficacy % beside each one. This
information can be found at
[1]http://scanmail.trustwave.com/?c=15517&a...
These vitamins and OTC meds should be given in a pack to every one with
Covid 19 and their close contacts:
Vitamin D 81%
Vitamin A 79%
Quercetin 79%
Melatonin 78%
Zinc 74%
Povidone-Iodine 71%
Vitamin C 43%
Aspirin 21%
The Ministry of Health should also have enough Budesonide and inhalers for
100,000 people.”
As COVID-19 is a viral illness, there is no specific treatment. Most
people who develop COVID-19 will recover fully while isolating at home or
in managed isolation and quarantine and they do not require
hospitalisation. Supportive treatment with fluid, rest, and antifever
medication is useful in aiding recovery and can be successfully managed by
a general practitioner (GP). A GP is best placed to provide care for those
who are recovering from COVID-19 at home, as they are familiar with
underlying conditions that may impact recovery and can manage these
appropriately.
For patients who are hospitalised with serious cases of COVID-19, there is
currently one Medsafe approved medication which is dexamethasone. It is an
anti-inflammatory medication that is indicated in the treatment of
COVID-19 for patients who require supplemental oxygen therapy. You can
find the Medsafe datasheet for the approved medicine
here: [2]www.medsafe.govt.nz/profs/Datasheet/d/Dexmethsonetab.pdf.
Medical practitioners are permitted to use any medicine for a particular
patient in their care at their discretion; however, unapproved medicines
have not been evaluated by Medsafe for safety and efficacy. If your
healthcare professional chose to prescribe other agents to treat a patient
with COVID-19 it would be their responsibility to ensure that they are
aware of any safety issues and that they communicate the risks and
benefits to their patients.
See [3]www.medsafe.govt.nz/COVID-19/medicine-approval-process.asp.
The Ministry of Health is aware that therapeutics will have a role to play
in managing the pandemic for people who are not vaccinated. Medicines and
other ways to treat and manage patients who have COVID-19 are being
continually developed and researched. You can find more information on
COVID-19 treatments on the Ministry of Health website
here: [4]www.health.govt.nz/our-work/diseases-and-conditions/covid-19-novel-coronavirus/covid-19-health-advice-public/about-covid-19.
However, as previously advised, the Ministry of Health does not conduct
the treatment of patients, therefore cannot provide guidance regarding the
treatment protocols that is in the hospitals, general practitioners or
district health boards.
Under section 28(3) of the Act you have the right to ask the Ombudsman to
review any decisions made under this request. The Ombudsman may be
contacted by email at: [5][email address] or by calling 0800
802 602.
Ngâ mihi,
OIA Services
Government Services
Office of the Director-General
Ministry of Health
E: [email address]
****************************************************************************
Statement of confidentiality: This e-mail message and any accompanying
attachments may contain information that is IN-CONFIDENCE and subject to
legal privilege.
If you are not the intended recipient, do not read, use, disseminate,
distribute or copy this message or attachments.
If you have received this message in error, please notify the sender
immediately and delete this message.
****************************************************************************
--------------------------------------------------------------------------
This e-mail message has been scanned for Viruses and Content and cleared
by the Ministry of Health's Content and Virus Filtering Gateway
--------------------------------------------------------------------------
References
Visible links
1. http://scanmail.trustwave.com/?c=15517&a...
2. https://www.medsafe.govt.nz/profs/Datash...
3. http://www.medsafe.govt.nz/COVID-19/medi...
4. https://www.health.govt.nz/our-work/dise...
5. mailto:[email address]
hide quoted sections
From: Micky Turner
Dear MOH OIA Requests,
If the Ministry of Health is not responsible for ensuring medical supplies are available for the treatment of patients and the prevention of virus infection in the population:
Who authorized the Pfizer vaccine and Remdesivir?
Who has overseen the bulk supply of PPE during this pandemic?
Yours sincerely,
Micky Turner
From: OIA Requests
Kia ora,
Thank you for your Official Information Act (the Act) request. This is
an automatic reply to let you know we received it.
Due to the COVID-19 global pandemic response, the Ministry is experiencing
significantly higher volumes of queries and requests for information. We
will endeavour to acknowledge your request as soon as possible. Further
information about COVID-19 can be found on our
website: [1]https://www.health.govt.nz/our-work/dise...
Please be advised that due dates for requests received from 29 November
2021 onwards take into account the following periods:
Christmas (25 December 2021)
Summer Holidays (25 December to 15 January)
New Year's Day (1 January 2022)
Day after News Year's Day (2 January 2022)
If you'd like to calculate the due date for your request, you can use the
Ombudsman's online calculator here: [2]http://www.ombudsman.parliament.nz/
If you have any questions while we're processing your request, please let
us know via [3][email address]
Ngā mihi
OIA Services Team
[4]Ministry of Health information releases
[5]Unite against COVID-19
****************************************************************************
Statement of confidentiality: This e-mail message and any accompanying
attachments may contain information that is IN-CONFIDENCE and subject to
legal privilege.
If you are not the intended recipient, do not read, use, disseminate,
distribute or copy this message or attachments.
If you have received this message in error, please notify the sender
immediately and delete this message.
****************************************************************************
--------------------------------------------------------------------------
This e-mail message has been scanned for Viruses and Content and cleared
by the Ministry of Health's Content and Virus Filtering Gateway
--------------------------------------------------------------------------
References
Visible links
1. https://www.health.govt.nz/our-work/dise...
2. http://scanmail.trustwave.com/?c=15517&a...
3. mailto:[email address]
4. https://www.health.govt.nz/about-ministr...
5. https://covid19.govt.nz/
hide quoted sections
From: Micky Turner
Dear Ministry of Health,
I note also that Dexamethasone which you are using has a very small benefit and 'only' if patients are on oxygen.
_____________
Primary endpoint
Mortality at 28 days was significantly lower in the dexamethasone group than in the usual
care group, with deaths reported in 482 of 2104 patients (22.9%) and in 1110 of 4321
patients (25.7%), respectively (rate ratio, 0.83; 95% confidence interval [CI], 0.75 to 0.93;
P<0.001).
____________
2.7% less deaths is of course significant. However Aspirin results in 4% less deaths. Vitamin D results in 50-63% less deaths (late treatment). Budesonide 39% improvement (late treatment).
So if the Ministry of Health is not analyzing and ensuring medicines are available for New Zealanders - I really wonder what the purpose of the Ministry of Health is.
https://c19aspirin.com/
https://vdmeta.com/#fig_fpcd
https://vitamindforall.org/letter.html
https://c19budesonide.com/
The type of Vitamin D is also important:
Late stage treatment with calcifediol/calcitriol shows greater improvement compared to cholecalciferol: 78% [67‑85%] vs. 45% [24‑60%].
Yours faithfully,
Micky Turner
From: OIA Requests
Kia ora Micky
Thank you for your follow up email regarding your request for information.
Please refer to the following pages on the Pharmac website for information
about Remdesivir:
[1]www.pharmac.govt.nz/news-and-resources/covid19/funded-treatments-tocilizumab-and-remdesivir/
and
[2]www.pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-2021-09-16-remdesivir-to-treat-covid-19/.
Medsafe has provided provisional approval of the Pfizer vaccine. Further
information can be found on their website:
[3]www.medsafe.govt.nz/COVID-19/status-of-applications.asp and
specifically the Gazette
notice: [4]https://www.medsafe.govt.nz/COVID-19/Com...
You might also be interested in the information available on the Beehive
website regarding the Government’s approval for Pfizer to be used in New
Zealand:
[5]www.beehive.govt.nz/release/ministers-sign-use-first-covid-19-vaccine.
Personal Protective Equipment (PPE) for New Zealand's COVID-19 response is
sourced and distributed as part of a nationally coordinated approach,
managed by the Ministry of Health. Further information can be found on our
website:
[6]www.health.govt.nz/our-work/diseases-and-conditions/covid-19-novel-coronavirus/covid-19-information-specific-audiences/covid-19-personal-protective-equipment-central-supply.
Under section 28(3) of the Act, you have the right to ask the Ombudsman to
review any decisions made under this request. The Ombudsman may be
contacted by email at: [7][email address] or by calling 0800
802 602.
Ngā mihi,
OIA Services
Government Services
Office of the Director-General
Ministry of Health
E: [email address]
From: Micky Turner <[8][FOI #17557 email]>
Sent: Thursday, 2 December 2021 10:06
To: OIA Requests <[9][email address]>
Subject: Re: Your request for information, ref: H202116568
Dear MOH OIA Requests,
If the Ministry of Health is not responsible for ensuring medical supplies
are available for the treatment of patients and the prevention of virus
infection in the population:
Who authorized the Pfizer vaccine and Remdesivir?
Who has overseen the bulk supply of PPE during this pandemic?
Yours sincerely,
Micky Turner
-----Original Message-----
Tçnâ koe Micky
Thank you for your request under the Official Information Act 1982 (the
Act) to the Ministry of Health (the Ministry) on 13 November 2021 for:
“Can you please advise if you are offering people with Covid-19 any of
the
following:
Fluvoxamine 89%
Budesonide 81%
Vitamin D 81%
Vitamin A 79%
Quercetin 79%
Melatonin 78%
Zinc 74%
Povidone-Iodine 71%
Sotrovimab 67%
Ivermectin 67%
Vitamin C 43%
Aspirin 21%
I have included their early treatment efficacy % beside each one. This
information can be found at
[1][10]http://scanmail.trustwave.com/?c=15517&a...
These vitamins and OTC meds should be given in a pack to every one with
Covid 19 and their close contacts:
Vitamin D 81%
Vitamin A 79%
Quercetin 79%
Melatonin 78%
Zinc 74%
Povidone-Iodine 71%
Vitamin C 43%
Aspirin 21%
The Ministry of Health should also have enough Budesonide and inhalers
for
100,000 people.”
As COVID-19 is a viral illness, there is no specific treatment. Most
people who develop COVID-19 will recover fully while isolating at home or
in managed isolation and quarantine and they do not require
hospitalisation. Supportive treatment with fluid, rest, and antifever
medication is useful in aiding recovery and can be successfully managed
by
a general practitioner (GP). A GP is best placed to provide care for
those
who are recovering from COVID-19 at home, as they are familiar with
underlying conditions that may impact recovery and can manage these
appropriately.
For patients who are hospitalised with serious cases of COVID-19, there
is
currently one Medsafe approved medication which is dexamethasone. It is
an
anti-inflammatory medication that is indicated in the treatment of
COVID-19 for patients who require supplemental oxygen therapy. You can
find the Medsafe datasheet for the approved medicine
here: [2][11]www.medsafe.govt.nz/profs/Datasheet/d/Dexmethsonetab.pdf.
Medical practitioners are permitted to use any medicine for a particular
patient in their care at their discretion; however, unapproved medicines
have not been evaluated by Medsafe for safety and efficacy. If your
healthcare professional chose to prescribe other agents to treat a
patient
with COVID-19 it would be their responsibility to ensure that they are
aware of any safety issues and that they communicate the risks and
benefits to their patients.
See [3][12]www.medsafe.govt.nz/COVID-19/medicine-approval-process.asp.
The Ministry of Health is aware that therapeutics will have a role to
play
in managing the pandemic for people who are not vaccinated. Medicines and
other ways to treat and manage patients who have COVID-19 are being
continually developed and researched. You can find more information on
COVID-19 treatments on the Ministry of Health website
here: [4][13]www.health.govt.nz/our-work/diseases-and-conditions/covid-19-novel-coronavirus/covid-19-health-advice-public/about-covid-19.
However, as previously advised, the Ministry of Health does not conduct
the treatment of patients, therefore cannot provide guidance regarding
the
treatment protocols that is in the hospitals, general practitioners or
district health boards.
Under section 28(3) of the Act you have the right to ask the Ombudsman to
review any decisions made under this request. The Ombudsman may be
contacted by email at: [5][email address] or by calling 0800
802 602.
Ngâ mihi,
OIA Services
Government Services
Office of the Director-General
Ministry of Health
E: [email address]
References
Visible links
1.
[14]http://scanmail.trustwave.com/?c=15517&a...
2. [15]https://www.medsafe.govt.nz/profs/Datash...
3. [16]http://www.medsafe.govt.nz/COVID-19/medi...
4.
[17]https://www.health.govt.nz/our-work/dise...
5. [18]mailto:[email address]
-------------------------------------------------------------------
Please use this email address for all replies to this request:
[19][FOI #17557 email]
Disclaimer: This message and any reply that you make will be published on
the internet. Our privacy and copyright policies:
[20]https://scanmail.trustwave.com/?c=15517&...
If you find this service useful as an Official Information officer, please
ask your web manager to link to us from your organisation's OIA or LGOIMA
page.
-------------------------------------------------------------------
****************************************************************************
Statement of confidentiality: This e-mail message and any accompanying
attachments may contain information that is IN-CONFIDENCE and subject to
legal privilege.
If you are not the intended recipient, do not read, use, disseminate,
distribute or copy this message or attachments.
If you have received this message in error, please notify the sender
immediately and delete this message.
****************************************************************************
--------------------------------------------------------------------------
This e-mail message has been scanned for Viruses and Content and cleared
by the Ministry of Health's Content and Virus Filtering Gateway
--------------------------------------------------------------------------
References
Visible links
1. http://www.pharmac.govt.nz/news-and-reso...
2. http://www.pharmac.govt.nz/news-and-reso...
3. https://www.medsafe.govt.nz/COVID-19/sta...
4. https://www.medsafe.govt.nz/COVID-19/Com...
5. https://www.beehive.govt.nz/release/mini...
6. https://www.health.govt.nz/our-work/dise...
7. mailto:[email address]
8. mailto:[FOI #17557 email]
9. mailto:[email address]
10. http://scanmail.trustwave.com/?c=15517&a...
11. http://www.medsafe.govt.nz/profs/Datashe...
12. http://www.medsafe.govt.nz/COVID-19/medi...
13. http://www.health.govt.nz/our-work/disea...
14. http://scanmail.trustwave.com/?c=15517&a...
15. https://www.medsafe.govt.nz/profs/Datash...
16. http://www.medsafe.govt.nz/COVID-19/medi...
17. https://www.health.govt.nz/our-work/dise...
18. mailto:[email
19. mailto:[FOI #17557 email]
20. https://scanmail.trustwave.com/?c=15517&...
hide quoted sections
From: Micky Turner
Dear OIA Requests,
Thanks,
So the vaccine has been signed off by the Minister of Health.
Remdesivir - we actually don't know which doctor signed this off from the documents - so will assume it was Ashley Bloomfield.
Without question the people ultimately responsible for ensuring medications are available to New Zealanders are Ashley Bloomfield and Andrew Little. Both have independent emergency legislative powers to approve and purchase medicines.
Some responsibility also sits with the Covid 19 response team who have been tasked with analyzing and advising on potential solutions and treatments.
Yours sincerely,
Micky Turner
Things to do with this request
- Add an annotation (to help the requester or others)
- Download a zip file of all correspondence